Once-Daily Raltegravir Safe, Effective for Initial HIV Treatment
Once-daily regimens have been shown to improve adherence to treatment with no adverse effect on outcomes in patients with HIV.
Emerging Treatments in HIV
Emerging Treatments in HIV
Latest News
FDA Panel Votes on Treatment for Extensively Drug Resistant, Multidrug Resistant TB
The FDA’s Antimicrobial Drugs Advisory Committee voted in favor of pretomanid, as part of a combination regimen with bedaquiline and linezolid, for the treatment of pulmonary extensively drug resistant, treatment intolerant, or nonresponsive multidrug resistant tuberculosis.
Ceftolozane/Tazobactam Approved for Hospital-Acquired Bacterial Pneumonia
Zerbaxa has been approved for a new indication to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
Fofomycin Injection: New Drug Application for Treatment of Complicated UTI
Contepo, an investigational epoxide intravenous (IV) antibiotic, has broad spectrum activity against Gram-negative and Gram-positive pathogens, including multi-drug resistant strains such as ESBL-producing Enterobacteriaceae.
TOL-463 Effective for Bacterial Vaginosis and Vulvovaginal Candidiasis
TOL-463, particularly in vaginal insert form, is effective and safe in treating bacterial vaginosis and vulvovaginal candidiasis.
Ampicillin Plus Ceftriaxone: An Effective Alternative for E faecalis Infective Endocarditis
Ampicillin plus ceftriaxone was an effective treatment for penicillin-susceptible Enterococcus faecalis infective endocarditis compared with ampicillin plus gentamicin.
Continuous Antibiotic Infusion via Elastomeric Pumps Safe and Effective in Outpatients
Treating outpatients with continuous infusions of flucloxacillin, cefepime, vancomycin, and piperacillin/tazobactam using elastomeric pumps was effective and safe.
Could Zika Virus Be a Potential Treatment for Neuroblastoma?
Even with intensive therapy, survival among neuroblastoma patients is poor, indicating a need for alternative treatments.
Zemdri Now Available for the Treatment of Complicated UTI, Pyelonephritis
Zemdri carries a Boxed Warning describing reports of nephrotoxicity, ototoxicity, and neuromuscular blockade, as well as fetal harm if administered during pregnancy.
TPOXX Approved for the Treatment of Human Smallpox Disease
The approval was supported by findings from 12 clinical trials of TPOXX with more than 700 healthy volunteers that showed no drug-related serious adverse events.
Gilead Submits NDA for Triple-Therapy, Single Tablet HIV Regimen
Gilead submitted their single-tablet regimen containing bictegravir, emtricitabine, and tenofovir alafenamide for HIV-1 treatment to the FDA.
Pitavastatin Lowers Cholesterol More Effectively Than Pravastatin in HIV
Pitavastatin reduced low-density lipoprotein cholesterol to a greater extent than pravastatin with a similar safety profile in patients with HIV and dyslipidemia.
FDA Green Lights Odefsey for Treating HIV-1
Combining emtricitabine and tenofovir alafenamide (Gilead Sciences) and rilpivirine (Janssen Sciences), Odefsey is Gilead’s second tenofovir alafenamide-based regimen to receive FDA approval.
Drop-to-Drop Variation Noted With Fingerprick Blood
Authors say variation in blood analytes holds implications for point-of-care testing.
Combination HIV Antiretroviral Promising To Rid Body of HIV For Months
The URMC-099 compound combined with antiretroviral therapy significantly reduced HIV levels.
Rifamycin-ART, Other Medication Dosing Errors Noted With TB Therapy
More than half of study patients had at least one medication error linked to antituberculosis therapy.
FDA Approves Label Changes For Olysio Use in HIV Co-Infection, HCV Genotype 4
The Food and Drug Administration (FDA) has approved label changes for simeprevir; (Olysio, Janssen) to include dosing recommendations for the treatment of hepatitis C virus (HCV)/HIV-1 co-infection.
New HIV Combination Medication Meets Primary Objective
Gilead announced that phase 3 study evaluating its investigational fixed-dose combination of emtricitabine and tenofovir alafenamide (F/TAF) for the treatment of HIV-1 infection met its primary objective.
Genes May Hold The Key To A Better HIV Vaccine
Findings challenge one-shot-fits-all approach, could guide development of future vaccines.
HIV Treatment Label Gets Updated Pediatric Use Subsection
The FDA announced that the product label for Kaletra (lopinavir/ritonavir; AbbVie) has been updated to include drug interaction information and to update the Specific Populations, Pediatric Use subsection.
Want to read more?
Please login or register first to view this content.
Next post in Emerging Treatments
